Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024)
Avalo Therapeutics (AVTX) posted Preferred Stock Liabilities of $1.7 million for Q3 2024, down 85.53% on a QoQ basis from $11.5 million in Q2 2024.
Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024) Analysis & Trends
Avalo Therapeutics' Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $1.7 million for Q3 2024.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $1.7 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.7 million (changed N/A YoY) and the FY2014 annual result came in at $28.3 million, up 42.75% from the prior year.
- Preferred Stock Liabilities was $1.7 million for Q3 2024 at Avalo Therapeutics, down from $11.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $11.5 million in Q1 2024 and bottomed at $1.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 11.46 Mn |
| Mar 31, 2024 | 11.46 Mn |
| Sep 30, 2015 | 28.35 Mn |
| Dec 31, 2014 | 28.35 Mn |